AEOL-10150 (Aeolus)

Curr Opin Investig Drugs. 2006 Jan;7(1):70-80.

Abstract

AEOL-10150, a small-molecule antioxidant analogous to the catalytic site of superoxide dismutase, is under development by Aeolus (formerly Incara) as a potential subcutaneous treatment for amyotrophic lateral sclerosis (ALS), stroke, spinal cord injury, lung inflammation and mucositis. The compound is currently undergoing a phase I clinical trial for ALS. In October 2005, the company had applied for Fast Track status, and planned to submit a special protocol assessment for a pivotal phase II/III trial.

Publication types

  • Review

MeSH terms

  • Animals
  • Antioxidants / adverse effects
  • Antioxidants / chemistry
  • Antioxidants / pharmacokinetics
  • Antioxidants / therapeutic use*
  • Clinical Trials as Topic
  • Humans
  • Lung Diseases / drug therapy
  • Metalloporphyrins / adverse effects
  • Metalloporphyrins / chemistry
  • Metalloporphyrins / pharmacology
  • Metalloporphyrins / therapeutic use*
  • Molecular Structure
  • Neoplasms / drug therapy
  • Nervous System Diseases / drug therapy
  • Neuroprotective Agents / adverse effects
  • Neuroprotective Agents / chemistry
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Structure-Activity Relationship
  • Treatment Outcome

Substances

  • AEOL 10150
  • Antioxidants
  • Metalloporphyrins
  • Neuroprotective Agents